Deepika Jalota Sells 4,104 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Stock

PMV Pharmaceuticals, Inc. (NASDAQ:PMVPGet Free Report) insider Deepika Jalota sold 4,104 shares of the stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $6.62, for a total value of $27,168.48. Following the transaction, the insider now directly owns 29,946 shares in the company, valued at approximately $198,242.52. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

PMV Pharmaceuticals Stock Down 7.5 %

NASDAQ PMVP traded down $0.50 during midday trading on Monday, hitting $6.21. The company had a trading volume of 265,103 shares, compared to its average volume of 488,016. The firm has a fifty day simple moving average of $7.02 and a two-hundred day simple moving average of $5.94. The stock has a market cap of $300.94 million, a price-to-earnings ratio of -3.87 and a beta of 0.93. PMV Pharmaceuticals, Inc. has a fifty-two week low of $3.84 and a fifty-two week high of $13.02.

PMV Pharmaceuticals (NASDAQ:PMVPGet Free Report) last released its quarterly earnings data on Wednesday, August 9th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.09. As a group, equities analysts predict that PMV Pharmaceuticals, Inc. will post -1.67 earnings per share for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright lowered their target price on shares of PMV Pharmaceuticals from $35.00 to $29.00 and set a “buy” rating on the stock in a research note on Friday, August 11th.

Read Our Latest Research Report on PMV Pharmaceuticals

Institutional Investors Weigh In On PMV Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Alliancebernstein L.P. increased its position in shares of PMV Pharmaceuticals by 5.6% during the 2nd quarter. Alliancebernstein L.P. now owns 49,090 shares of the company’s stock worth $307,000 after purchasing an additional 2,590 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in PMV Pharmaceuticals by 124.7% in the second quarter. Wells Fargo & Company MN now owns 14,649 shares of the company’s stock valued at $92,000 after buying an additional 8,131 shares during the period. Fishman Jay A Ltd. MI lifted its stake in shares of PMV Pharmaceuticals by 20.0% in the 2nd quarter. Fishman Jay A Ltd. MI now owns 30,000 shares of the company’s stock valued at $188,000 after purchasing an additional 5,000 shares during the period. Woodline Partners LP lifted its stake in PMV Pharmaceuticals by 317.2% in the second quarter. Woodline Partners LP now owns 733,735 shares of the company’s stock valued at $4,593,000 after buying an additional 557,847 shares during the period. Finally, XTX Topco Ltd bought a new position in PMV Pharmaceuticals during the 2nd quarter worth approximately $170,000.

PMV Pharmaceuticals Company Profile

(Get Free Report)

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.

See Also

Receive News & Ratings for PMV Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PMV Pharmaceuticals and related companies with's FREE daily email newsletter.